6 results about "Brain Thrombus" patented technology

The application discloses a method for identifying the properties of intracranial high-density foci after thrombectomy of acute ischemic stroke based on multi-time sequence and multi-modalities, which comprises the following steps: acquiring sampling data, wherein the sampling data comprises multi-time sequence image data and multi-modal clinical data; performing preprocessing and registration labeling based on the acquired sampling data to obtain consistent data; performing dynamic change feature extraction on the consistent data by using a pre-trained multi-time sequence and multi-modality deep learning model, realizing multi-modality feature fusion based on the extracted dynamic change features, obtaining fusion features, identifying feature labels based on the fusion features, and outputting detection results. The application discloses a method and system for identifying the properties of intracranial high-density foci after thrombectomy of acute ischemic stroke based on multi-time sequence and multi-modalities, and provides effective reference identification data.

This invention discloses a brain-targeting neutrophil membrane-encapsulated tanshinone IIa PLGA nanoparticle formulation, its preparation method, and its uses. The brain-targeting tanshinone IIa nanoparticle formulation, Neu-Tan-IIa@PLGA, is characterized by comprising a PLGA-loaded tanshinone IIa nanoparticle core (Tan-IIa@PLGA) and an outer neutrophil membrane coating. This invention effectively overcomes the problems of poor water solubility, low oral bioavailability, and difficulty in crossing the blood-brain barrier associated with tanshinone IIa. This invention provides a tanshinone IIa with strong targeting and high drug stability, enabling delivery to lesions in ischemic brain regions and improving the safety and efficacy of stroke treatment.

This application relates to the fields of biomedical engineering and neuromodulation, disclosing the application of ultrashortwave in the fabrication of devices for modulating brain neural activity. The modulation of brain neural activity is achieved through the non-thermal effects of ultrashortwave, which refers to ultrashortwave with a frequency of 27.12MHz ± 0.6%, a wavelength of 11.06 nm, and a power of 1.6 ± 0.72 W. This application breaks through the traditional technical prejudice that high-frequency electric fields are unsuitable for the central nervous system, proving that non-thermal ultrashortwave can be safely used for brain neural modulation, opening up a completely new technical direction for neural modulation. With "ultrashortwave + application scenario" as its core protection element, it provides fundamental patent support for research on the treatment of various central nervous system diseases such as Parkinson's disease, stroke, depression, and Alzheimer's disease, possessing extremely high core patent value and broad clinical translation prospects.

The application provides a method for constructing a local inflammation model of an experimental animal brain, which comprises the following steps: anesthetizing the experimental animal and fixing the experimental animal on a positioning device; injecting an immunomodulator into a target region according to the coordinates of the target region by using a puncture tool; controlling the injection speed and dose of the immunomodulator by using a micro-infusion device; keeping the puncture needle in the body for a period of time after injection to reduce the backflow of the liquid medicine; verifying the local immune activation by quantitatively detecting the expression change of an inflammation marker in the target region, and synchronously detecting the expression level of the inflammation marker in a peripheral medium to exclude a systemic immune response. The application can effectively solve the problem that the peripheral inflammation effect is difficult to distinguish in the research of brain diseases caused by systemic administration in the prior art, and can be applied to the research of the local immune activation effect of diseases such as Alzheimer's disease, ischemic stroke and glioblastoma, and the evaluation of the efficacy and mechanism of STING agonists in these diseases.

This application relates to the field of intelligent healthcare, specifically to a method, device, and program product for assessing vascular occlusion reperfusion therapy based on thrombus permeability. It includes acquiring brain images of patients with acute ischemic stroke; classifying the responsible vessel in the brain images to determine whether it is large vessel occlusion, medium vessel occlusion, or distal small vessel occlusion; when the determination result is medium vessel occlusion, thrombus region localization and measurement are performed on the brain images, thrombus permeability is calculated, and reperfusion therapy is assessed based on the thrombus permeability to obtain an assessment result for intravenous thrombolysis or endovascular therapy. This application has significant clinical application value.

This invention provides a drug delivery system and its application based on brain microvascular endothelial cells, comprising stimulated brain microvascular endothelial cells, wherein the stimulation is performed by culturing in a culture system containing supernatant of brain microvascular endothelial cells cultured under glucose and oxygen deprivation. This invention solves the problems of targeting and timeliness in treating blood-brain barrier damage after ischemic stroke under current technologies. It can regulate the BBB while supporting its function and structure, maintaining and repairing BBB function after reperfusion, thus improving the prognosis of stroke treatment. The cell preparations in this invention are widely available and easily obtained, and can rapidly repair the blood-brain barrier. Furthermore, the cell preparations in this invention can target ischemic brain sites and can be administered via simple intravenous injection, facilitating clinical operation.